New combo shows promise for tough stomach cancer
NCT ID NCT03223376
First seen Jan 04, 2026 · Last updated May 23, 2026 · Updated 18 times
Summary
This study tested a new drug combination (fruquintinib plus paclitaxel) in 703 people with advanced stomach cancer that had gotten worse after initial treatment. The goal was to see if the combo helps people live longer and controls the cancer better than paclitaxel alone. The approach aims to manage the disease, not cure it, as ongoing treatment is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Huchison Medi Pharma Investigational site
Nanjing, Jiangsu, 210000, China
-
Hutchison Medi Pharma Invesigational sites
Hefei, Anhui, 230000, China
-
Hutchison Medi Pharma Investigational Site
Guangzhou, Guangdong, 510030, China
-
Hutchison Medi Pharma Investigational site
Harbin, Heilongjiang, 150081, China
-
Hutchison Medi Pharma Investigational site
Shanghai, 200125, China
-
Hutchison Medi Pharma Investigational sites
Hangzhou, Zhejiang, 310000, China
-
Hutchison Medi Pharma Investigational sites
Beijing, 100142, China
Conditions
Explore the condition pages connected to this study.